Get the Stockscreener App
8.96
6.00%
0.37
Cns Pharmaceuticals Inc stock is traded at $8.96, with a volume of 39,437.
It is up +6.00% in the last 24 hours and down -5.16% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$8.59
Open:
$8.61
24h Volume:
39,437
Relative Volume:
0.29
Market Cap:
$44.84M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.1267
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
-5.16%
1M Performance:
-5.16%
6M Performance:
-85.66%
1Y Performance:
-98.66%
1-Day Range:
$8.51
$9.45
1-Week Range:
$7.72
$9.62
52-Week Range:
$7.72
$692.64
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
8.79 | 44.84M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.00 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.50 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.16 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
590.66 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.68 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
What drives CNS Pharmaceuticals Inc. stock priceFree Stock Movement Tracking - Autocar Professional
CNS Pharmaceuticals Inc. Stock Analysis and ForecastPowerful market insights - Autocar Professional
What analysts say about CNS Pharmaceuticals Inc. stockFree Consultation - Autocar Professional
Is CNS Pharmaceuticals Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com
Why CNS Pharmaceuticals Inc. stock attracts strong analyst attentionPrecision Entry Strategy - beatles.ru
CNS Pharmaceuticals Announces Reverse Stock Split - TipRanks
CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference - 富途牛牛
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Featured In Virtual Investor Summer Spotlight Conference - Barchart.com
CNS Pharmaceuticals CEO Shares Brain Cancer Treatment Vision at Investor Conference | CNSP Stock News - Stock Titan
CNS Pharmaceuticals To Carry Out 1-for-12 Reverse Stock Split On July 22nd, 2025 - 富途牛牛
CNS Pharmaceuticals Implements 1-for-12 Reverse Stock Split to Consolidate Shares and Improve Market Position - AInvest
Published on: 2025-07-19 01:04:34 - jammulinksnews.com
CNS Pharmaceuticals (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22 - Barchart.com
CNS Pharmaceuticals announces 1-for-12 reverse stock split By Investing.com - Investing.com Canada
CNS Pharmaceuticals announces 1-for-12 reverse stock split - Investing.com
Brain Cancer Drug Developer CNS Pharmaceuticals Announces 1:12 Reverse Split to Maintain Nasdaq Listing - Stock Titan
How CNS Pharmaceuticals Inc. stock performs during market volatility3x Growth Potential - Newser
CNS Pharmaceuticals Posts Investor Presentation on Brain Cancer - TipRanks
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
What makes CNS Pharmaceuticals Inc. stock price move sharplySmart Money Trade Setups - Newser
Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform - Yahoo Finance
Jazz Looks To Block Avadel From Asking For Sleep Drug OK - Law360
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Lead Program In Virtual CEO Segment - Barchart.com
CNS Pharmaceuticals: TPI 287 Shows Potential in Treating CNS Tumors, CEO Discusses Recent Clinical Data at Virtual Investor CEO Connect Segment - AInvest
CNS Pharma CEO Shares Exclusive Insights on Novel Brain Cancer Treatment TPI 287 at Healthcare Leaders Meeting - Stock Titan
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment - FinancialContent
CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 2% – Here’s What Happened - Defense World
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights GBM Treatment Insights In KOL Segment Featuring Dr. Erin Dunbar - Barchart.com
CNS Pharmaceuticals Inc. Sheds Light on GBM Treatment Advances in KOL Segment with Dr. Erin Dunbar - citybuzz -
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Featuring Dr. Erin Dunbar Discussing Glioblastoma Multiforme and Lead Product Candidate TPI 287 - AInvest
Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com
Revolutionary Nasal Drug Delivery System Could Transform Treatment of Opioid Overdose and Epilepsy - Stock Titan
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):